Evidence map›Paper›PMID 38250203›Full record

ArticleOpen forum infectious diseases2024

Burden of Medically Attended Diarrhea and Outpatient

Sara Y Tartof, Mark A Schmidt, Richard Contreras, Frederick J Angulo, Ana Florea, Joanna L Barreras, Judy Donald, Joann Zamparo, Deborah Ling Grant, Elizabeth Shuster and 2 more

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Sara Y TartofDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0000-0003-2336-8476
Mark A SchmidtDepartment of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, USA.
Richard ContrerasDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
Frederick J AnguloVaccines, Antivirals, and Evidence Generation, Pfizer Inc, NewYork, New York, USA.
Ana FloreaDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0000-0003-0030-8737
Joanna L BarrerasDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
Judy DonaldScience Programs Department, Kaiser Permanente Northwest Center for Health Research, Portland, Oregon, USA.
Joann ZamparoVaccines, Antivirals, and Evidence Generation, Pfizer Inc, NewYork, New York, USA.
Deborah Ling GrantDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
Elizabeth ShusterScience Programs Department, Kaiser Permanente Northwest Center for Health Research, Portland, Oregon, USA.
Elisa GonzalezVaccines, Antivirals, and Evidence Generation, Pfizer Inc, NewYork, New York, USA.
Jennifer L KuntzScience Programs Department, Kaiser Permanente Northwest Center for Health Research, Portland, Oregon, USA.
Kaiser Permanente · USKaiser Permanente Center for Health Research · USPfizer (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Identification of Methods: This was a retrospective cohort study among members ≥18 years of age from Kaiser Permanente Southern California and Kaiser Permanente Northwest from 1 January 2016 through 31 December 2021. MAD was identified by outpatient diarrheal Results: We identified 777 533 MAD episodes; 12.1% (93 964/777 533) were tested for CDI. Of those tested, 10.8% (10 110/93 964) were positive. Outpatient CDI IR was 51.0 (95% confidence interval [CI], 49.8-52.2) per 100 000 person-years, decreasing from 58.2 (95% CI, 55.7-60.7) in 2016 to 45.7 (95% CI, 43.7-47.8) in 2021. Approximately 44% (n = 4200) received an antibiotic 30 days prior to index date and 84.1% (n = 8006) CDIs were "community-associated" (no hospitalizations 12 weeks prior to index date). Of outpatient CDIs, 6.7% (n = 526) had a CDI-associated hospitalization ≤12 months. Conclusions: There was a high incidence of outpatient CDI despite infrequent CDI testing among patients with MAD. The majority of those with outpatient CDI had no recent antibiotic use and no recent hospitalization. Further studies are needed to understand the source and management of medically attended outpatient CDI.

Indexed as

Clostridioides difficilediarrheaincidenceKaiser Permanentereal-world

Identifiers

PMID38250203
PMCPMC10798856
OpenAlexW4390753296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.